ImmunotherapyHumansMaleFemaleNeoplasmsImmune Checkpoint Inhibitors
Consequences of adverse events in cancer immunotherapy combinations - a comprehensive real-world analysis.
Siv Gyda Aanes, Carsten Nieder, David Westfall Bates, Siri Wiig, Ellinor Christin Haukland
Published: 202510.1080/1750743X.2025.2600847
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) are pivotal in systemic anticancer therapy. The aim of the study was to investigate incidence, severity and consequences of immune-related adverse events (irAEs) in ICI combinations by comparing differe…
Preview only. Read the full abstract at the source